AI Terminal
Pharmanutra
Business and Financial Review • Mar 17, 2025
4324_rns_2025-03-17_608c80bf-f50d-4a4f-a5a8-0f476a01ceca.pdf
Business and Financial Review
Open in ViewerOpens in native device viewer
| Informazione Regolamentata n. 20106-8-2025 |
Data/Ora Inizio Diffusione 17 Marzo 2025 13:28:10 |
Euronext Star Milan | |
|---|---|---|---|
| Societa' | : | PHARMANUTRA | |
| Identificativo Informazione Regolamentata |
: | 202514 | |
| Utenza - Referente | : | PHARMANUTRAN04 - Roberto Lacorte | |
| Tipologia | : | 1.1 | |
| Data/Ora Ricezione | : | 17 Marzo 2025 13:28:10 | |
| Data/Ora Inizio Diffusione | : | 17 Marzo 2025 13:28:10 | |
| Oggetto | : | Pharmanutra PR clarification and integration note |
|
| Testo del comunicato |
Vedi allegato
PHARMANUTRA S.P.A. CLARIFICATIONNOTE ONTHE PRESS RELEASE OF 14 MARCH 2025 WITH RESPECT TO THE BUSINESS OUTLOOK
Pisa,17 March 2025 - To supplement and clarify what was reported in the press release of Friday, 14 March in the third paragraph of the section 'Business Outlook', PharmaNutra S.p.A. (MTA; Ticker PHN) specifies that there are no specific critical issues that may arise from 'the unpredictable developments of scenarios related to the current geopolitical situation that generate a generalised macroeconomic uncertainty' that may affect the achievement of the company's objectives. In particular, no significant impact is expected from the possible introduction of customs duties on Group products destined for the American market.
PharmaNutra S.p.A.
Founded and led by the President Andrea Lacorte and Vice President Roberto Lacorte, PharmaNutra was established in 2003. It develops unique nutritional supplements and innovative nutritional devices, handling the entire production process, from proprietary raw materials to finished product. PharmaNutra is a leader in the production of iron-based nutritional supplements with the SiderAL® brand, where it can claim important Sucrosomial® Technology patents, and is considered one of the top players in the sector of medical devices dedicated to the restoration of joint capacity thanks to the Cetilar® brand, now on the market also with Cetilar® Nutrition, a line of supplements designed for those who practice sport constantly. Over the years the Group - present abroad in over 89 countries - has developed precise strategy for the management and production of intellectual property, founded on the integrated management of all the various elements: proprietary raw materials, patents, brands and clinical evidence. PharmaNutra.it
For further information:
Via Delle Lenze, 216/b - 56122 Pisa Tel. +39 050 7846500 [email protected]
Internal Press Office [email protected]
PharmaNutra S.p.A. Press Office - Spriano Communication & Partners
Via Santa Radegonda, 16 - 20121 Milan Tel. +39 02 83635708
Matteo Russo [email protected] Cristina Tronconi [email protected]
PharmaNutra S.p.A. Sede Legale Via Campodavela, 1 - 56122 Pisa | +39 050 7846500 pharmanutra.it | [email protected] | [email protected] C.F. / P.Iva / Reg. Impr. 01679440501 - Codice SDI SUBM70N Cap.Soc. € 1.123.097,70 I.V. | REA 146259
| Numero di Pagine: 3 |
|---|